tirzepatide surpass 4 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Body weight loss with tirzepatide

Research suggests cycles of up to 12 weeks with breaks in between to maintain efficacy and prevent tolerance

LSN3318839 anchors in the TM1-TM2 cleft by extensively interacting with residues in TM1, TM2 and GLP-1(9-36) ( Fig

Causes of Melanonychia: Melanonychia can have various causes, ranging from benign to potentially serious conditions

The addition of the glucagon receptor is particularly significant, as it addresses energy expenditure and hepatic lipid metabolism in ways that GLP-1 and GIP agonists cannot achieve in isolation

A 2022 study published in Diabetes, Obesity and Metabolism found that adults over 50 achieved clinically significant weight loss on semaglutide, with cardiovascular and metabolic risk reductions comparable to younger cohorts, though the authors noted the importance of individualized monitoring protocols for older patients given the higher baseline prevalence of comorbidities